Tanuja Chitnis, MD

The division chief of neuroimmunology at Brigham and Women’s Hospital provided clinical insights on a recently published study in JAMA Neurology covering EBNA-1 antibodies as a diagnostic clue in neuroinflammatory diseases like multiple sclerosis. [WATCH TIME: 4 minutes]

The division chief of neuroimmunology at Brigham and Women’s Hospital discusses longitudinal EBNA-1 antibody data and its potential role as a complementary biomarker to distinguish MS from related neuroinflammatory diseases.

Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, answer questions about biomarkers in MS care.

Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, discuss future directions in MS amid increasing advances in the field.

Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, discuss the limitations of neurofilament light chain in identifying disease progression.

Mark Freedman, MD, MSc; Tanuja Chitnis, MD; and Ahmed Obeidat, MD, PhD, discusses the challenges associated with the cost of MRI and other important tools in the monitoring and assessment of MS.

Tanuja Chitnis, MD, discusses the CLIMB database and study to identify predictors of future disease and determine the effect of treatment on progressions and disability.

Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, contextualize data from large studies regarding the utilization of neurofilament light chain.

Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, discuss how use of biomarkers has affected understanding and assessment of lesion types.

Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, review conditions under which they would assess treatment success for patients who have changed therapies.

Thought leaders explore treatment possibilities in patients with irregular NFL patterns.

Tanuja Chitnis, MD, shares possible course of action if NFL levels begin to rise during treatment.

Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, raise important questions about the extent to which biomarkers can aid in patient care as well as their limitations.

Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, talk about the practical use of biomarkers in treatment decision making.

Tanuja Chitnis, MD, explains how higher neurofilament light chain levels can signal disease activity in MS.

Ahmed Obeidat, MD, PhD, recounts the difficulties with MRI as a main biomarker for MS and shares strategies for optimal use of the technology.

Tanuja Chitnis, MD, discusses the use of ultra-sensitive assays to determine protein levels in the blood, which may aid in the diagnosis of MS.

Ahmed Obeidat, MD, PhD, considers utility of biomarkers in MS diagnosis, but he also noted that diagnosis remains clinical.

Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, discuss the role of biomarkers and the key areas in which they will be used in managing day-to-day decisions in patient management.

The associate neurologist at Brigham and Women’s Hospital provided insight on the current state of promising targets in progressive MS and why anti-CD3 therapy might be a new consideration for future trials. [WATCH TIME: 2 minutes]

The associate neurologist at Brigham and Women’s Hospital provided background on a new case study of a patient with progressive MS who showed positive outcomes using foralumab, an anti-CD3 targeting agent. [WATCH TIME: 3 minutes]

Tanuja Chitnis, MD and Lauren B. Krupp, MD give insight into the future of pediatric multiple sclerosis by discussing unmet needs and advice for community neurologists.

Expert neurologists discuss drugs in development for pediatric multiple sclerosis and consider the potential for biomarkers to monitor treatment response or new disease activity in the future.

Lauren B. Krupp, MD considers how treatment failure in pediatric multiple sclerosis may be defined as disease relapse, new or enlarging legions, inability to tolerate treatment, or lack of adherence.

Leaders in neurology provide insight into first-line disease-modifying therapies for relapsing-remitting multiple sclerosis, such as interferon or glatiramer acetate, and glucocorticoids for acute events.

Tanuja Chitnis, MD reviews the 2018 AAN guidelines on disease-modifying therapies and discusses goals of therapy when selecting first-line treatments and monitoring response in pediatric multiple sclerosis.

Experts in multiple sclerosis discuss the importance of a multidisciplinary approach for pediatric patients and emphasize the role of social workers, psychologists, and support groups for patients and families.  

Expert neurologist Lauren B. Krupp, MD provides insight into the use of diagnostic tools for pediatric multiple sclerosis such as MRI imaging, laboratory blood tests, and lumbar punctures.

Key opinion leaders in the management of MS comment on the current diagnostic criteria and discuss the importance of ruling out other common mimics in pediatric patients.

Lauren B. Krupp, MD provides insight into the signs and symptoms of multiple sclerosis and emphasizes differences in clinical presentation between adult and pediatric patients.